Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26

Benzinga · 2d ago
Stifel analyst Jonathan Block upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $22 to $26.